nodes	percent_of_prediction	percent_of_DWPC	metapath
Paclitaxel—ovarian cancer—testicular cancer	0.182	0.378	CtDrD
Paclitaxel—kidney cancer—testicular cancer	0.152	0.317	CtDrD
Paclitaxel—lung cancer—testicular cancer	0.147	0.305	CtDrD
Paclitaxel—TUBB2B—Vinblastine—testicular cancer	0.0243	0.0633	CbGbCtD
Paclitaxel—TUBB4A—Vinblastine—testicular cancer	0.0243	0.0633	CbGbCtD
Paclitaxel—TUBB3—Vinblastine—testicular cancer	0.0243	0.0633	CbGbCtD
Paclitaxel—TUBB2A—Vinblastine—testicular cancer	0.0243	0.0633	CbGbCtD
Paclitaxel—TUBB6—Vinblastine—testicular cancer	0.0243	0.0633	CbGbCtD
Paclitaxel—TUBB8—Vinblastine—testicular cancer	0.0243	0.0633	CbGbCtD
Paclitaxel—TUBB—Vinblastine—testicular cancer	0.0204	0.053	CbGbCtD
Paclitaxel—TUBB4B—Vinblastine—testicular cancer	0.0204	0.053	CbGbCtD
Paclitaxel—TUBB1—Vinblastine—testicular cancer	0.0204	0.053	CbGbCtD
Paclitaxel—ABCC10—Etoposide—testicular cancer	0.014	0.0365	CbGbCtD
Paclitaxel—ABCC1—Dactinomycin—testicular cancer	0.00959	0.0249	CbGbCtD
Paclitaxel—ABCC10—Doxorubicin—testicular cancer	0.00956	0.0249	CbGbCtD
Paclitaxel—ABCC10—Methotrexate—testicular cancer	0.00926	0.0241	CbGbCtD
Paclitaxel—ABCB11—Vinblastine—testicular cancer	0.00846	0.022	CbGbCtD
Paclitaxel—ABCC1—Epirubicin—testicular cancer	0.00695	0.0181	CbGbCtD
Paclitaxel—ABCG2—Dactinomycin—testicular cancer	0.00642	0.0167	CbGbCtD
Paclitaxel—ABCC1—Vinblastine—testicular cancer	0.00601	0.0156	CbGbCtD
Paclitaxel—CYP3A7—Ifosfamide—testicular cancer	0.0056	0.0146	CbGbCtD
Paclitaxel—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0056	0.0146	CbGbCtD
Paclitaxel—ABCC1—Etoposide—testicular cancer	0.00541	0.0141	CbGbCtD
Paclitaxel—ABCB11—Doxorubicin—testicular cancer	0.0052	0.0135	CbGbCtD
Paclitaxel—CYP1B1—Doxorubicin—testicular cancer	0.0052	0.0135	CbGbCtD
Paclitaxel—SLCO1B3—Methotrexate—testicular cancer	0.00517	0.0135	CbGbCtD
Paclitaxel—ABCC2—Carboplatin—testicular cancer	0.00477	0.0124	CbGbCtD
Paclitaxel—ABCC2—Vinblastine—testicular cancer	0.00445	0.0116	CbGbCtD
Paclitaxel—ABCG2—Carboplatin—testicular cancer	0.00431	0.0112	CbGbCtD
Paclitaxel—CYP3A5—Ifosfamide—testicular cancer	0.0042	0.0109	CbGbCtD
Paclitaxel—ABCC2—Cisplatin—testicular cancer	0.00408	0.0106	CbGbCtD
Paclitaxel—CYP2C8—Ifosfamide—testicular cancer	0.00404	0.0105	CbGbCtD
Paclitaxel—ABCC2—Etoposide—testicular cancer	0.00401	0.0104	CbGbCtD
Paclitaxel—CYP19A1—corpus luteum—testicular cancer	0.00372	0.107	CbGeAlD
Paclitaxel—ABCC1—Doxorubicin—testicular cancer	0.00369	0.0096	CbGbCtD
Paclitaxel—ABCG2—Cisplatin—testicular cancer	0.00369	0.00959	CbGbCtD
Paclitaxel—ABCG2—Etoposide—testicular cancer	0.00362	0.00942	CbGbCtD
Paclitaxel—ABCC1—Methotrexate—testicular cancer	0.00358	0.0093	CbGbCtD
Paclitaxel—CYP19A1—seminiferous tubule of testis—testicular cancer	0.00315	0.0908	CbGeAlD
Paclitaxel—CYP2C9—Ifosfamide—testicular cancer	0.00282	0.00733	CbGbCtD
Paclitaxel—ABCC2—Doxorubicin—testicular cancer	0.00273	0.00711	CbGbCtD
Paclitaxel—ABCC2—Methotrexate—testicular cancer	0.00265	0.00689	CbGbCtD
Paclitaxel—ABCG2—Doxorubicin—testicular cancer	0.00247	0.00643	CbGbCtD
Paclitaxel—ABCG2—Methotrexate—testicular cancer	0.00239	0.00623	CbGbCtD
Paclitaxel—ABCB1—Dactinomycin—testicular cancer	0.00231	0.00602	CbGbCtD
Paclitaxel—CYP3A5—Etoposide—testicular cancer	0.00201	0.00522	CbGbCtD
Paclitaxel—CYP2C8—Etoposide—testicular cancer	0.00193	0.00502	CbGbCtD
Paclitaxel—CYP19A1—semen—testicular cancer	0.00174	0.0502	CbGeAlD
Paclitaxel—CYP3A4—Ifosfamide—testicular cancer	0.00164	0.00426	CbGbCtD
Paclitaxel—ABCB1—Vinblastine—testicular cancer	0.00145	0.00377	CbGbCtD
Paclitaxel—CYP2C9—Cisplatin—testicular cancer	0.00137	0.00356	CbGbCtD
Paclitaxel—ABCB1—Cisplatin—testicular cancer	0.00133	0.00346	CbGbCtD
Paclitaxel—ABCB1—Etoposide—testicular cancer	0.00131	0.0034	CbGbCtD
Paclitaxel—MAP4—embryo—testicular cancer	0.000977	0.0282	CbGeAlD
Paclitaxel—ABCB1—Doxorubicin—testicular cancer	0.000891	0.00232	CbGbCtD
Paclitaxel—CYP3A4—Vinblastine—testicular cancer	0.000868	0.00226	CbGbCtD
Paclitaxel—ABCB1—Methotrexate—testicular cancer	0.000863	0.00224	CbGbCtD
Paclitaxel—CYP3A4—Etoposide—testicular cancer	0.000782	0.00204	CbGbCtD
Paclitaxel—MAP2—embryo—testicular cancer	0.00077	0.0222	CbGeAlD
Paclitaxel—MAP2—seminal vesicle—testicular cancer	0.000723	0.0208	CbGeAlD
Paclitaxel—TUBB8—testis—testicular cancer	0.000701	0.0202	CbGeAlD
Paclitaxel—MAP4—gonad—testicular cancer	0.000663	0.0191	CbGeAlD
Paclitaxel—MAPT—testis—testicular cancer	0.000608	0.0175	CbGeAlD
Paclitaxel—BCL2—gonad—testicular cancer	0.000603	0.0174	CbGeAlD
Paclitaxel—TUBB4A—embryo—testicular cancer	0.000595	0.0171	CbGeAlD
Paclitaxel—TUBB2B—seminal vesicle—testicular cancer	0.00054	0.0156	CbGeAlD
Paclitaxel—MAP4—female gonad—testicular cancer	0.000539	0.0155	CbGeAlD
Paclitaxel—CYP3A4—Doxorubicin—testicular cancer	0.000534	0.00139	CbGbCtD
Paclitaxel—MAP2—gonad—testicular cancer	0.000522	0.0151	CbGeAlD
Paclitaxel—TUBB—seminal vesicle—testicular cancer	0.000511	0.0147	CbGeAlD
Paclitaxel—TUBB2A—seminal vesicle—testicular cancer	0.000508	0.0146	CbGeAlD
Paclitaxel—TUBB6—seminal vesicle—testicular cancer	0.000501	0.0144	CbGeAlD
Paclitaxel—BCL2—female gonad—testicular cancer	0.00049	0.0141	CbGeAlD
Paclitaxel—TUBB3—testis—testicular cancer	0.000478	0.0138	CbGeAlD
Paclitaxel—MAP4—testis—testicular cancer	0.000478	0.0138	CbGeAlD
Paclitaxel—TUBB1—testis—testicular cancer	0.000468	0.0135	CbGeAlD
Paclitaxel—TUBB4B—embryo—testicular cancer	0.000464	0.0134	CbGeAlD
Paclitaxel—MAPT—lymph node—testicular cancer	0.000441	0.0127	CbGeAlD
Paclitaxel—ABCC10—seminal vesicle—testicular cancer	0.000439	0.0127	CbGeAlD
Paclitaxel—TUBB4B—seminal vesicle—testicular cancer	0.000436	0.0126	CbGeAlD
Paclitaxel—BCL2—testis—testicular cancer	0.000435	0.0125	CbGeAlD
Paclitaxel—MAP2—female gonad—testicular cancer	0.000425	0.0122	CbGeAlD
Paclitaxel—TUBB4A—gonad—testicular cancer	0.000404	0.0116	CbGeAlD
Paclitaxel—TUBB2B—gonad—testicular cancer	0.00039	0.0112	CbGeAlD
Paclitaxel—MAP2—testis—testicular cancer	0.000377	0.0109	CbGeAlD
Paclitaxel—TUBB6—gonad—testicular cancer	0.000362	0.0104	CbGeAlD
Paclitaxel—ABCB11—testis—testicular cancer	0.000361	0.0104	CbGeAlD
Paclitaxel—MAP4—lymph node—testicular cancer	0.000347	0.00999	CbGeAlD
Paclitaxel—CYP19A1—Ovarian Infertility Genes—DAZL—testicular cancer	0.00033	0.145	CbGpPWpGaD
Paclitaxel—TUBB4A—female gonad—testicular cancer	0.000328	0.00946	CbGeAlD
Paclitaxel—ABCC10—gonad—testicular cancer	0.000317	0.00914	CbGeAlD
Paclitaxel—TUBB2B—female gonad—testicular cancer	0.000317	0.00914	CbGeAlD
Paclitaxel—BCL2—lymph node—testicular cancer	0.000315	0.00908	CbGeAlD
Paclitaxel—TUBB4B—gonad—testicular cancer	0.000315	0.00908	CbGeAlD
Paclitaxel—ABCC1—seminal vesicle—testicular cancer	0.00031	0.00895	CbGeAlD
Paclitaxel—TUBB—female gonad—testicular cancer	0.0003	0.00865	CbGeAlD
Paclitaxel—TUBB2A—female gonad—testicular cancer	0.000298	0.0086	CbGeAlD
Paclitaxel—TUBB6—female gonad—testicular cancer	0.000294	0.00848	CbGeAlD
Paclitaxel—TUBB4A—testis—testicular cancer	0.000291	0.00839	CbGeAlD
Paclitaxel—TUBB2B—testis—testicular cancer	0.000281	0.00811	CbGeAlD
Paclitaxel—MAP2—lymph node—testicular cancer	0.000273	0.00787	CbGeAlD
Paclitaxel—CYP19A1—gonad—testicular cancer	0.000267	0.00769	CbGeAlD
Paclitaxel—TUBB—testis—testicular cancer	0.000266	0.00767	CbGeAlD
Paclitaxel—TUBB2A—testis—testicular cancer	0.000265	0.00763	CbGeAlD
Paclitaxel—TUBB6—testis—testicular cancer	0.000261	0.00753	CbGeAlD
Paclitaxel—ABCC10—female gonad—testicular cancer	0.000258	0.00743	CbGeAlD
Paclitaxel—ABCG2—seminal vesicle—testicular cancer	0.000257	0.00741	CbGeAlD
Paclitaxel—TUBB4B—female gonad—testicular cancer	0.000256	0.00738	CbGeAlD
Paclitaxel—CYP1B1—gonad—testicular cancer	0.000249	0.00719	CbGeAlD
Paclitaxel—ABCC10—testis—testicular cancer	0.000229	0.00659	CbGeAlD
Paclitaxel—TUBB4B—testis—testicular cancer	0.000227	0.00654	CbGeAlD
Paclitaxel—CYP19A1—female gonad—testicular cancer	0.000217	0.00625	CbGeAlD
Paclitaxel—TUBB4A—lymph node—testicular cancer	0.000211	0.00608	CbGeAlD
Paclitaxel—TUBB2B—lymph node—testicular cancer	0.000204	0.00588	CbGeAlD
Paclitaxel—CYP1B1—female gonad—testicular cancer	0.000203	0.00584	CbGeAlD
Paclitaxel—TUBB—lymph node—testicular cancer	0.000193	0.00556	CbGeAlD
Paclitaxel—CYP19A1—testis—testicular cancer	0.000192	0.00554	CbGeAlD
Paclitaxel—TUBB2A—lymph node—testicular cancer	0.000192	0.00553	CbGeAlD
Paclitaxel—TUBB6—lymph node—testicular cancer	0.000189	0.00545	CbGeAlD
Paclitaxel—ABCC2—testis—testicular cancer	0.000184	0.00529	CbGeAlD
Paclitaxel—ABCC1—female gonad—testicular cancer	0.000182	0.00525	CbGeAlD
Paclitaxel—CYP1B1—testis—testicular cancer	0.00018	0.00518	CbGeAlD
Paclitaxel—MAP2—LKB1 signaling events—STK11—testicular cancer	0.000166	0.0733	CbGpPWpGaD
Paclitaxel—ABCC10—lymph node—testicular cancer	0.000166	0.00478	CbGeAlD
Paclitaxel—TUBB4B—lymph node—testicular cancer	0.000165	0.00474	CbGeAlD
Paclitaxel—ABCC1—testis—testicular cancer	0.000162	0.00466	CbGeAlD
Paclitaxel—ABCG2—female gonad—testicular cancer	0.000151	0.00435	CbGeAlD
Paclitaxel—CYP3A5—female gonad—testicular cancer	0.00014	0.00404	CbGeAlD
Paclitaxel—CYP19A1—lymph node—testicular cancer	0.000139	0.00402	CbGeAlD
Paclitaxel—CYP2C8—testis—testicular cancer	0.000138	0.00397	CbGeAlD
Paclitaxel—ABCB1—embryo—testicular cancer	0.000135	0.00389	CbGeAlD
Paclitaxel—ABCG2—testis—testicular cancer	0.000134	0.00386	CbGeAlD
Paclitaxel—ABCC2—lymph node—testicular cancer	0.000133	0.00383	CbGeAlD
Paclitaxel—CYP1B1—lymph node—testicular cancer	0.00013	0.00376	CbGeAlD
Paclitaxel—ABCB1—seminal vesicle—testicular cancer	0.000127	0.00365	CbGeAlD
Paclitaxel—ABCC1—lymph node—testicular cancer	0.000117	0.00338	CbGeAlD
Paclitaxel—ABCG2—lymph node—testicular cancer	9.7e-05	0.0028	CbGeAlD
Paclitaxel—MAPT—LKB1 signaling events—STK11—testicular cancer	9.32e-05	0.0411	CbGpPWpGaD
Paclitaxel—ABCB1—gonad—testicular cancer	9.16e-05	0.00264	CbGeAlD
Paclitaxel—ABCB1—female gonad—testicular cancer	7.44e-05	0.00214	CbGeAlD
Paclitaxel—MAPT—Kit receptor signaling pathway—KITLG—testicular cancer	6.69e-05	0.0295	CbGpPWpGaD
Paclitaxel—ABCB1—testis—testicular cancer	6.6e-05	0.0019	CbGeAlD
Paclitaxel—ABCC10—Transmembrane transport of small molecules—SLC2A6—testicular cancer	5.41e-05	0.0238	CbGpPWpGaD
Paclitaxel—ABCC2—NRF2 pathway—SLC2A6—testicular cancer	5.19e-05	0.0229	CbGpPWpGaD
Paclitaxel—BCL2—C-MYB transcription factor network—MAD1L1—testicular cancer	4.84e-05	0.0213	CbGpPWpGaD
Paclitaxel—ABCB1—lymph node—testicular cancer	4.78e-05	0.00138	CbGeAlD
Paclitaxel—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—KITLG—testicular cancer	4.63e-05	0.0204	CbGpPWpGaD
Paclitaxel—SLCO1B3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	4.57e-05	0.0201	CbGpPWpGaD
Paclitaxel—MAPT—Kit receptor signaling pathway—KIT—testicular cancer	4.57e-05	0.0201	CbGpPWpGaD
Paclitaxel—CYP1B1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	4.53e-05	0.02	CbGpPWpGaD
Paclitaxel—ABCC1—Arachidonic acid metabolism—HPGDS—testicular cancer	4.38e-05	0.0193	CbGpPWpGaD
Paclitaxel—CYP1B1—Arachidonic acid metabolism—HPGDS—testicular cancer	4.24e-05	0.0187	CbGpPWpGaD
Paclitaxel—BCL2—Kit receptor signaling pathway—KITLG—testicular cancer	4.12e-05	0.0181	CbGpPWpGaD
Paclitaxel—MAPT—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	3.89e-05	0.0171	CbGpPWpGaD
Paclitaxel—MAPT—LPA receptor mediated events—MMP2—testicular cancer	3.79e-05	0.0167	CbGpPWpGaD
Paclitaxel—TUBB6—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.42e-05	0.0151	CbGpPWpGaD
Paclitaxel—TUBB2B—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.42e-05	0.0151	CbGpPWpGaD
Paclitaxel—BCL2—C-MYB transcription factor network—H2AFZ—testicular cancer	3.37e-05	0.0149	CbGpPWpGaD
Paclitaxel—TUBB3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.3e-05	0.0146	CbGpPWpGaD
Paclitaxel—TUBB2A—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.2e-05	0.0141	CbGpPWpGaD
Paclitaxel—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—KIT—testicular cancer	3.16e-05	0.0139	CbGpPWpGaD
Paclitaxel—TUBB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.13e-05	0.0138	CbGpPWpGaD
Paclitaxel—BCL2—C-MYB transcription factor network—KITLG—testicular cancer	3.1e-05	0.0137	CbGpPWpGaD
Paclitaxel—MAPT—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	2.83e-05	0.0125	CbGpPWpGaD
Paclitaxel—TUBB4A—Transmembrane transport of small molecules—SLC2A6—testicular cancer	2.81e-05	0.0124	CbGpPWpGaD
Paclitaxel—BCL2—Kit receptor signaling pathway—KIT—testicular cancer	2.81e-05	0.0124	CbGpPWpGaD
Paclitaxel—TUBB4B—Transmembrane transport of small molecules—SLC2A6—testicular cancer	2.57e-05	0.0113	CbGpPWpGaD
Paclitaxel—BCL2—ATF-2 transcription factor network—MMP2—testicular cancer	2.49e-05	0.011	CbGpPWpGaD
Paclitaxel—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	2.39e-05	0.0106	CbGpPWpGaD
Paclitaxel—BCL2—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	2.39e-05	0.0105	CbGpPWpGaD
Paclitaxel—SLCO1B3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	2.32e-05	0.0102	CbGpPWpGaD
Paclitaxel—Cardiac disorder—Methotrexate—testicular cancer	2.24e-05	0.000228	CcSEcCtD
Paclitaxel—Urinary tract disorder—Epirubicin—testicular cancer	2.23e-05	0.000227	CcSEcCtD
Paclitaxel—Oedema peripheral—Epirubicin—testicular cancer	2.23e-05	0.000226	CcSEcCtD
Paclitaxel—Haematuria—Doxorubicin—testicular cancer	2.22e-05	0.000225	CcSEcCtD
Paclitaxel—Connective tissue disorder—Epirubicin—testicular cancer	2.22e-05	0.000225	CcSEcCtD
Paclitaxel—Urethral disorder—Epirubicin—testicular cancer	2.22e-05	0.000225	CcSEcCtD
Paclitaxel—Hepatobiliary disease—Doxorubicin—testicular cancer	2.2e-05	0.000224	CcSEcCtD
Paclitaxel—Epistaxis—Doxorubicin—testicular cancer	2.2e-05	0.000223	CcSEcCtD
Paclitaxel—Angiopathy—Methotrexate—testicular cancer	2.19e-05	0.000222	CcSEcCtD
Paclitaxel—Sinusitis—Doxorubicin—testicular cancer	2.19e-05	0.000222	CcSEcCtD
Paclitaxel—Immune system disorder—Methotrexate—testicular cancer	2.18e-05	0.000221	CcSEcCtD
Paclitaxel—Visual impairment—Epirubicin—testicular cancer	2.18e-05	0.000221	CcSEcCtD
Paclitaxel—Mediastinal disorder—Methotrexate—testicular cancer	2.18e-05	0.000221	CcSEcCtD
Paclitaxel—Chills—Methotrexate—testicular cancer	2.17e-05	0.00022	CcSEcCtD
Paclitaxel—Nausea—Ifosfamide—testicular cancer	2.15e-05	0.000219	CcSEcCtD
Paclitaxel—Diarrhoea—Cisplatin—testicular cancer	2.14e-05	0.000217	CcSEcCtD
Paclitaxel—Erythema multiforme—Epirubicin—testicular cancer	2.14e-05	0.000217	CcSEcCtD
Paclitaxel—Alopecia—Methotrexate—testicular cancer	2.13e-05	0.000217	CcSEcCtD
Paclitaxel—Bradycardia—Doxorubicin—testicular cancer	2.13e-05	0.000216	CcSEcCtD
Paclitaxel—BCL2—C-MYB transcription factor network—KIT—testicular cancer	2.12e-05	0.00933	CbGpPWpGaD
Paclitaxel—Mental disorder—Methotrexate—testicular cancer	2.12e-05	0.000215	CcSEcCtD
Paclitaxel—Eye disorder—Epirubicin—testicular cancer	2.11e-05	0.000214	CcSEcCtD
Paclitaxel—Hypersensitivity—Etoposide—testicular cancer	2.11e-05	0.000214	CcSEcCtD
Paclitaxel—Tinnitus—Epirubicin—testicular cancer	2.11e-05	0.000214	CcSEcCtD
Paclitaxel—Malnutrition—Methotrexate—testicular cancer	2.1e-05	0.000213	CcSEcCtD
Paclitaxel—Erythema—Methotrexate—testicular cancer	2.1e-05	0.000213	CcSEcCtD
Paclitaxel—Haemoglobin—Doxorubicin—testicular cancer	2.1e-05	0.000213	CcSEcCtD
Paclitaxel—Cardiac disorder—Epirubicin—testicular cancer	2.1e-05	0.000213	CcSEcCtD
Paclitaxel—Flushing—Epirubicin—testicular cancer	2.1e-05	0.000213	CcSEcCtD
Paclitaxel—BCL2—Integrated Breast Cancer Pathway—STK11—testicular cancer	2.1e-05	0.00925	CbGpPWpGaD
Paclitaxel—Rhinitis—Doxorubicin—testicular cancer	2.1e-05	0.000213	CcSEcCtD
Paclitaxel—Haemorrhage—Doxorubicin—testicular cancer	2.09e-05	0.000212	CcSEcCtD
Paclitaxel—Hypoaesthesia—Doxorubicin—testicular cancer	2.08e-05	0.000211	CcSEcCtD
Paclitaxel—Pharyngitis—Doxorubicin—testicular cancer	2.08e-05	0.000211	CcSEcCtD
Paclitaxel—Urinary tract disorder—Doxorubicin—testicular cancer	2.07e-05	0.00021	CcSEcCtD
Paclitaxel—Oedema peripheral—Doxorubicin—testicular cancer	2.06e-05	0.000209	CcSEcCtD
Paclitaxel—Dysgeusia—Methotrexate—testicular cancer	2.06e-05	0.000209	CcSEcCtD
Paclitaxel—Asthenia—Etoposide—testicular cancer	2.06e-05	0.000209	CcSEcCtD
Paclitaxel—Connective tissue disorder—Doxorubicin—testicular cancer	2.06e-05	0.000209	CcSEcCtD
Paclitaxel—Angiopathy—Epirubicin—testicular cancer	2.05e-05	0.000208	CcSEcCtD
Paclitaxel—Urethral disorder—Doxorubicin—testicular cancer	2.05e-05	0.000208	CcSEcCtD
Paclitaxel—Immune system disorder—Epirubicin—testicular cancer	2.04e-05	0.000207	CcSEcCtD
Paclitaxel—Mediastinal disorder—Epirubicin—testicular cancer	2.04e-05	0.000207	CcSEcCtD
Paclitaxel—Back pain—Methotrexate—testicular cancer	2.03e-05	0.000206	CcSEcCtD
Paclitaxel—Chills—Epirubicin—testicular cancer	2.03e-05	0.000206	CcSEcCtD
Paclitaxel—Pruritus—Etoposide—testicular cancer	2.03e-05	0.000206	CcSEcCtD
Paclitaxel—Arrhythmia—Epirubicin—testicular cancer	2.02e-05	0.000205	CcSEcCtD
Paclitaxel—Visual impairment—Doxorubicin—testicular cancer	2.02e-05	0.000205	CcSEcCtD
Paclitaxel—Alopecia—Epirubicin—testicular cancer	2e-05	0.000203	CcSEcCtD
Paclitaxel—Vomiting—Cisplatin—testicular cancer	1.99e-05	0.000202	CcSEcCtD
Paclitaxel—Vision blurred—Methotrexate—testicular cancer	1.98e-05	0.000201	CcSEcCtD
Paclitaxel—Mental disorder—Epirubicin—testicular cancer	1.98e-05	0.000201	CcSEcCtD
Paclitaxel—Erythema multiforme—Doxorubicin—testicular cancer	1.98e-05	0.000201	CcSEcCtD
Paclitaxel—Rash—Cisplatin—testicular cancer	1.97e-05	0.0002	CcSEcCtD
Paclitaxel—Dermatitis—Cisplatin—testicular cancer	1.97e-05	0.0002	CcSEcCtD
Paclitaxel—Malnutrition—Epirubicin—testicular cancer	1.97e-05	0.0002	CcSEcCtD
Paclitaxel—Erythema—Epirubicin—testicular cancer	1.97e-05	0.0002	CcSEcCtD
Paclitaxel—Diarrhoea—Etoposide—testicular cancer	1.96e-05	0.000199	CcSEcCtD
Paclitaxel—Eye disorder—Doxorubicin—testicular cancer	1.95e-05	0.000198	CcSEcCtD
Paclitaxel—Ill-defined disorder—Methotrexate—testicular cancer	1.95e-05	0.000198	CcSEcCtD
Paclitaxel—Tinnitus—Doxorubicin—testicular cancer	1.95e-05	0.000198	CcSEcCtD
Paclitaxel—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	1.95e-05	0.00859	CbGpPWpGaD
Paclitaxel—Anaemia—Methotrexate—testicular cancer	1.94e-05	0.000197	CcSEcCtD
Paclitaxel—Cardiac disorder—Doxorubicin—testicular cancer	1.94e-05	0.000197	CcSEcCtD
Paclitaxel—Flushing—Doxorubicin—testicular cancer	1.94e-05	0.000197	CcSEcCtD
Paclitaxel—Flatulence—Epirubicin—testicular cancer	1.94e-05	0.000197	CcSEcCtD
Paclitaxel—Tension—Epirubicin—testicular cancer	1.93e-05	0.000196	CcSEcCtD
Paclitaxel—Dysgeusia—Epirubicin—testicular cancer	1.93e-05	0.000196	CcSEcCtD
Paclitaxel—Nervousness—Epirubicin—testicular cancer	1.91e-05	0.000194	CcSEcCtD
Paclitaxel—Back pain—Epirubicin—testicular cancer	1.9e-05	0.000193	CcSEcCtD
Paclitaxel—NR1I2—Gene Expression—DNMT3L—testicular cancer	1.9e-05	0.00837	CbGpPWpGaD
Paclitaxel—Angiopathy—Doxorubicin—testicular cancer	1.9e-05	0.000193	CcSEcCtD
Paclitaxel—Malaise—Methotrexate—testicular cancer	1.9e-05	0.000192	CcSEcCtD
Paclitaxel—Dizziness—Etoposide—testicular cancer	1.89e-05	0.000192	CcSEcCtD
Paclitaxel—Muscle spasms—Epirubicin—testicular cancer	1.89e-05	0.000192	CcSEcCtD
Paclitaxel—Immune system disorder—Doxorubicin—testicular cancer	1.89e-05	0.000192	CcSEcCtD
Paclitaxel—Vertigo—Methotrexate—testicular cancer	1.89e-05	0.000192	CcSEcCtD
Paclitaxel—Mediastinal disorder—Doxorubicin—testicular cancer	1.89e-05	0.000191	CcSEcCtD
Paclitaxel—Leukopenia—Methotrexate—testicular cancer	1.88e-05	0.000191	CcSEcCtD
Paclitaxel—Chills—Doxorubicin—testicular cancer	1.88e-05	0.000191	CcSEcCtD
Paclitaxel—Arrhythmia—Doxorubicin—testicular cancer	1.87e-05	0.00019	CcSEcCtD
Paclitaxel—Nausea—Cisplatin—testicular cancer	1.86e-05	0.000189	CcSEcCtD
Paclitaxel—Vision blurred—Epirubicin—testicular cancer	1.85e-05	0.000188	CcSEcCtD
Paclitaxel—Alopecia—Doxorubicin—testicular cancer	1.85e-05	0.000188	CcSEcCtD
Paclitaxel—Cough—Methotrexate—testicular cancer	1.84e-05	0.000186	CcSEcCtD
Paclitaxel—Mental disorder—Doxorubicin—testicular cancer	1.83e-05	0.000186	CcSEcCtD
Paclitaxel—Ill-defined disorder—Epirubicin—testicular cancer	1.83e-05	0.000185	CcSEcCtD
Paclitaxel—Convulsion—Methotrexate—testicular cancer	1.82e-05	0.000185	CcSEcCtD
Paclitaxel—Vomiting—Etoposide—testicular cancer	1.82e-05	0.000185	CcSEcCtD
Paclitaxel—Erythema—Doxorubicin—testicular cancer	1.82e-05	0.000185	CcSEcCtD
Paclitaxel—Malnutrition—Doxorubicin—testicular cancer	1.82e-05	0.000185	CcSEcCtD
Paclitaxel—Anaemia—Epirubicin—testicular cancer	1.82e-05	0.000185	CcSEcCtD
Paclitaxel—Agitation—Epirubicin—testicular cancer	1.81e-05	0.000184	CcSEcCtD
Paclitaxel—Rash—Etoposide—testicular cancer	1.81e-05	0.000183	CcSEcCtD
Paclitaxel—Dermatitis—Etoposide—testicular cancer	1.8e-05	0.000183	CcSEcCtD
Paclitaxel—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	1.8e-05	0.00793	CbGpPWpGaD
Paclitaxel—Headache—Etoposide—testicular cancer	1.79e-05	0.000182	CcSEcCtD
Paclitaxel—Flatulence—Doxorubicin—testicular cancer	1.79e-05	0.000182	CcSEcCtD
Paclitaxel—Myalgia—Methotrexate—testicular cancer	1.79e-05	0.000182	CcSEcCtD
Paclitaxel—Chest pain—Methotrexate—testicular cancer	1.79e-05	0.000182	CcSEcCtD
Paclitaxel—Arthralgia—Methotrexate—testicular cancer	1.79e-05	0.000182	CcSEcCtD
Paclitaxel—Tension—Doxorubicin—testicular cancer	1.79e-05	0.000181	CcSEcCtD
Paclitaxel—Dysgeusia—Doxorubicin—testicular cancer	1.78e-05	0.000181	CcSEcCtD
Paclitaxel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	1.78e-05	0.00018	CcSEcCtD
Paclitaxel—Malaise—Epirubicin—testicular cancer	1.77e-05	0.00018	CcSEcCtD
Paclitaxel—Discomfort—Methotrexate—testicular cancer	1.77e-05	0.00018	CcSEcCtD
Paclitaxel—Nervousness—Doxorubicin—testicular cancer	1.77e-05	0.00018	CcSEcCtD
Paclitaxel—Vertigo—Epirubicin—testicular cancer	1.77e-05	0.000179	CcSEcCtD
Paclitaxel—Syncope—Epirubicin—testicular cancer	1.76e-05	0.000179	CcSEcCtD
Paclitaxel—Leukopenia—Epirubicin—testicular cancer	1.76e-05	0.000179	CcSEcCtD
Paclitaxel—Back pain—Doxorubicin—testicular cancer	1.76e-05	0.000179	CcSEcCtD
Paclitaxel—Muscle spasms—Doxorubicin—testicular cancer	1.75e-05	0.000178	CcSEcCtD
Paclitaxel—Palpitations—Epirubicin—testicular cancer	1.74e-05	0.000177	CcSEcCtD
Paclitaxel—BCL2—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	1.74e-05	0.00766	CbGpPWpGaD
Paclitaxel—Confusional state—Methotrexate—testicular cancer	1.73e-05	0.000176	CcSEcCtD
Paclitaxel—Loss of consciousness—Epirubicin—testicular cancer	1.73e-05	0.000176	CcSEcCtD
Paclitaxel—Cough—Epirubicin—testicular cancer	1.72e-05	0.000174	CcSEcCtD
Paclitaxel—Anaphylactic shock—Methotrexate—testicular cancer	1.72e-05	0.000174	CcSEcCtD
Paclitaxel—Vision blurred—Doxorubicin—testicular cancer	1.72e-05	0.000174	CcSEcCtD
Paclitaxel—Convulsion—Epirubicin—testicular cancer	1.71e-05	0.000173	CcSEcCtD
Paclitaxel—Infection—Methotrexate—testicular cancer	1.71e-05	0.000173	CcSEcCtD
Paclitaxel—Nausea—Etoposide—testicular cancer	1.7e-05	0.000173	CcSEcCtD
Paclitaxel—Hypertension—Epirubicin—testicular cancer	1.7e-05	0.000172	CcSEcCtD
Paclitaxel—Ill-defined disorder—Doxorubicin—testicular cancer	1.69e-05	0.000171	CcSEcCtD
Paclitaxel—Nervous system disorder—Methotrexate—testicular cancer	1.68e-05	0.000171	CcSEcCtD
Paclitaxel—Anaemia—Doxorubicin—testicular cancer	1.68e-05	0.000171	CcSEcCtD
Paclitaxel—Thrombocytopenia—Methotrexate—testicular cancer	1.68e-05	0.000171	CcSEcCtD
Paclitaxel—Chest pain—Epirubicin—testicular cancer	1.68e-05	0.00017	CcSEcCtD
Paclitaxel—Arthralgia—Epirubicin—testicular cancer	1.68e-05	0.00017	CcSEcCtD
Paclitaxel—Myalgia—Epirubicin—testicular cancer	1.68e-05	0.00017	CcSEcCtD
Paclitaxel—Agitation—Doxorubicin—testicular cancer	1.67e-05	0.00017	CcSEcCtD
Paclitaxel—Anxiety—Epirubicin—testicular cancer	1.67e-05	0.000169	CcSEcCtD
Paclitaxel—Skin disorder—Methotrexate—testicular cancer	1.67e-05	0.000169	CcSEcCtD
Paclitaxel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	1.66e-05	0.000169	CcSEcCtD
Paclitaxel—ABCC2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.66e-05	0.00732	CbGpPWpGaD
Paclitaxel—Hyperhidrosis—Methotrexate—testicular cancer	1.66e-05	0.000168	CcSEcCtD
Paclitaxel—Discomfort—Epirubicin—testicular cancer	1.66e-05	0.000168	CcSEcCtD
Paclitaxel—Malaise—Doxorubicin—testicular cancer	1.64e-05	0.000167	CcSEcCtD
Paclitaxel—ABCC1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.64e-05	0.00723	CbGpPWpGaD
Paclitaxel—CYP19A1—Biological oxidations—HPGDS—testicular cancer	1.64e-05	0.00722	CbGpPWpGaD
Paclitaxel—Dry mouth—Epirubicin—testicular cancer	1.64e-05	0.000166	CcSEcCtD
Paclitaxel—Vertigo—Doxorubicin—testicular cancer	1.64e-05	0.000166	CcSEcCtD
Paclitaxel—Anorexia—Methotrexate—testicular cancer	1.64e-05	0.000166	CcSEcCtD
Paclitaxel—Syncope—Doxorubicin—testicular cancer	1.63e-05	0.000166	CcSEcCtD
Paclitaxel—Leukopenia—Doxorubicin—testicular cancer	1.63e-05	0.000165	CcSEcCtD
Paclitaxel—Confusional state—Epirubicin—testicular cancer	1.62e-05	0.000164	CcSEcCtD
Paclitaxel—Palpitations—Doxorubicin—testicular cancer	1.61e-05	0.000163	CcSEcCtD
Paclitaxel—Anaphylactic shock—Epirubicin—testicular cancer	1.61e-05	0.000163	CcSEcCtD
Paclitaxel—Oedema—Epirubicin—testicular cancer	1.61e-05	0.000163	CcSEcCtD
Paclitaxel—Hypotension—Methotrexate—testicular cancer	1.6e-05	0.000163	CcSEcCtD
Paclitaxel—Loss of consciousness—Doxorubicin—testicular cancer	1.6e-05	0.000162	CcSEcCtD
Paclitaxel—Infection—Epirubicin—testicular cancer	1.6e-05	0.000162	CcSEcCtD
Paclitaxel—Cough—Doxorubicin—testicular cancer	1.59e-05	0.000161	CcSEcCtD
Paclitaxel—Shock—Epirubicin—testicular cancer	1.58e-05	0.00016	CcSEcCtD
Paclitaxel—CYP1B1—Biological oxidations—HPGDS—testicular cancer	1.58e-05	0.00696	CbGpPWpGaD
Paclitaxel—Convulsion—Doxorubicin—testicular cancer	1.58e-05	0.00016	CcSEcCtD
Paclitaxel—Nervous system disorder—Epirubicin—testicular cancer	1.58e-05	0.00016	CcSEcCtD
Paclitaxel—TUBB—Cell Cycle, Mitotic—MAD1L1—testicular cancer	1.57e-05	0.00693	CbGpPWpGaD
Paclitaxel—Thrombocytopenia—Epirubicin—testicular cancer	1.57e-05	0.00016	CcSEcCtD
Paclitaxel—Hypertension—Doxorubicin—testicular cancer	1.57e-05	0.00016	CcSEcCtD
Paclitaxel—Tachycardia—Epirubicin—testicular cancer	1.57e-05	0.000159	CcSEcCtD
Paclitaxel—Musculoskeletal discomfort—Methotrexate—testicular cancer	1.56e-05	0.000159	CcSEcCtD
Paclitaxel—Skin disorder—Epirubicin—testicular cancer	1.56e-05	0.000158	CcSEcCtD
Paclitaxel—Hyperhidrosis—Epirubicin—testicular cancer	1.55e-05	0.000158	CcSEcCtD
Paclitaxel—Insomnia—Methotrexate—testicular cancer	1.55e-05	0.000158	CcSEcCtD
Paclitaxel—Arthralgia—Doxorubicin—testicular cancer	1.55e-05	0.000157	CcSEcCtD
Paclitaxel—Myalgia—Doxorubicin—testicular cancer	1.55e-05	0.000157	CcSEcCtD
Paclitaxel—Chest pain—Doxorubicin—testicular cancer	1.55e-05	0.000157	CcSEcCtD
Paclitaxel—Anxiety—Doxorubicin—testicular cancer	1.54e-05	0.000157	CcSEcCtD
Paclitaxel—Paraesthesia—Methotrexate—testicular cancer	1.54e-05	0.000156	CcSEcCtD
Paclitaxel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	1.54e-05	0.000156	CcSEcCtD
Paclitaxel—Discomfort—Doxorubicin—testicular cancer	1.53e-05	0.000155	CcSEcCtD
Paclitaxel—Anorexia—Epirubicin—testicular cancer	1.53e-05	0.000155	CcSEcCtD
Paclitaxel—Dyspnoea—Methotrexate—testicular cancer	1.53e-05	0.000155	CcSEcCtD
Paclitaxel—Somnolence—Methotrexate—testicular cancer	1.53e-05	0.000155	CcSEcCtD
Paclitaxel—Dry mouth—Doxorubicin—testicular cancer	1.52e-05	0.000154	CcSEcCtD
Paclitaxel—Dyspepsia—Methotrexate—testicular cancer	1.51e-05	0.000153	CcSEcCtD
Paclitaxel—Hypotension—Epirubicin—testicular cancer	1.5e-05	0.000152	CcSEcCtD
Paclitaxel—Confusional state—Doxorubicin—testicular cancer	1.5e-05	0.000152	CcSEcCtD
Paclitaxel—Decreased appetite—Methotrexate—testicular cancer	1.49e-05	0.000151	CcSEcCtD
Paclitaxel—Anaphylactic shock—Doxorubicin—testicular cancer	1.49e-05	0.000151	CcSEcCtD
Paclitaxel—Oedema—Doxorubicin—testicular cancer	1.49e-05	0.000151	CcSEcCtD
Paclitaxel—Gastrointestinal disorder—Methotrexate—testicular cancer	1.48e-05	0.00015	CcSEcCtD
Paclitaxel—Fatigue—Methotrexate—testicular cancer	1.48e-05	0.00015	CcSEcCtD
Paclitaxel—Infection—Doxorubicin—testicular cancer	1.48e-05	0.00015	CcSEcCtD
Paclitaxel—Pain—Methotrexate—testicular cancer	1.47e-05	0.000149	CcSEcCtD
Paclitaxel—Musculoskeletal discomfort—Epirubicin—testicular cancer	1.46e-05	0.000149	CcSEcCtD
Paclitaxel—Shock—Doxorubicin—testicular cancer	1.46e-05	0.000148	CcSEcCtD
Paclitaxel—Nervous system disorder—Doxorubicin—testicular cancer	1.46e-05	0.000148	CcSEcCtD
Paclitaxel—Thrombocytopenia—Doxorubicin—testicular cancer	1.46e-05	0.000148	CcSEcCtD
Paclitaxel—Insomnia—Epirubicin—testicular cancer	1.45e-05	0.000147	CcSEcCtD
Paclitaxel—Tachycardia—Doxorubicin—testicular cancer	1.45e-05	0.000147	CcSEcCtD
Paclitaxel—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	1.44e-05	0.00637	CbGpPWpGaD
Paclitaxel—Skin disorder—Doxorubicin—testicular cancer	1.44e-05	0.000147	CcSEcCtD
Paclitaxel—Paraesthesia—Epirubicin—testicular cancer	1.44e-05	0.000146	CcSEcCtD
Paclitaxel—Hyperhidrosis—Doxorubicin—testicular cancer	1.44e-05	0.000146	CcSEcCtD
Paclitaxel—Dyspnoea—Epirubicin—testicular cancer	1.43e-05	0.000145	CcSEcCtD
Paclitaxel—Somnolence—Epirubicin—testicular cancer	1.43e-05	0.000145	CcSEcCtD
Paclitaxel—CYP3A7—Biological oxidations—HPGDS—testicular cancer	1.42e-05	0.00627	CbGpPWpGaD
Paclitaxel—Anorexia—Doxorubicin—testicular cancer	1.42e-05	0.000144	CcSEcCtD
Paclitaxel—Feeling abnormal—Methotrexate—testicular cancer	1.41e-05	0.000144	CcSEcCtD
Paclitaxel—Dyspepsia—Epirubicin—testicular cancer	1.41e-05	0.000143	CcSEcCtD
Paclitaxel—TUBB—Cell Cycle—MAD1L1—testicular cancer	1.41e-05	0.0062	CbGpPWpGaD
Paclitaxel—Gastrointestinal pain—Methotrexate—testicular cancer	1.4e-05	0.000142	CcSEcCtD
Paclitaxel—Decreased appetite—Epirubicin—testicular cancer	1.4e-05	0.000142	CcSEcCtD
Paclitaxel—Hypotension—Doxorubicin—testicular cancer	1.39e-05	0.000141	CcSEcCtD
Paclitaxel—Gastrointestinal disorder—Epirubicin—testicular cancer	1.39e-05	0.000141	CcSEcCtD
Paclitaxel—Fatigue—Epirubicin—testicular cancer	1.38e-05	0.000141	CcSEcCtD
Paclitaxel—Constipation—Epirubicin—testicular cancer	1.37e-05	0.000139	CcSEcCtD
Paclitaxel—Pain—Epirubicin—testicular cancer	1.37e-05	0.000139	CcSEcCtD
Paclitaxel—Urticaria—Methotrexate—testicular cancer	1.36e-05	0.000138	CcSEcCtD
Paclitaxel—Abdominal pain—Methotrexate—testicular cancer	1.36e-05	0.000138	CcSEcCtD
Paclitaxel—Body temperature increased—Methotrexate—testicular cancer	1.36e-05	0.000138	CcSEcCtD
Paclitaxel—Musculoskeletal discomfort—Doxorubicin—testicular cancer	1.35e-05	0.000137	CcSEcCtD
Paclitaxel—Insomnia—Doxorubicin—testicular cancer	1.34e-05	0.000136	CcSEcCtD
Paclitaxel—Paraesthesia—Doxorubicin—testicular cancer	1.33e-05	0.000135	CcSEcCtD
Paclitaxel—Dyspnoea—Doxorubicin—testicular cancer	1.32e-05	0.000134	CcSEcCtD
Paclitaxel—Feeling abnormal—Epirubicin—testicular cancer	1.32e-05	0.000134	CcSEcCtD
Paclitaxel—CYP19A1—Integrated Breast Cancer Pathway—STK11—testicular cancer	1.32e-05	0.00582	CbGpPWpGaD
Paclitaxel—Somnolence—Doxorubicin—testicular cancer	1.32e-05	0.000134	CcSEcCtD
Paclitaxel—Gastrointestinal pain—Epirubicin—testicular cancer	1.31e-05	0.000133	CcSEcCtD
Paclitaxel—Dyspepsia—Doxorubicin—testicular cancer	1.31e-05	0.000133	CcSEcCtD
Paclitaxel—TUBB4A—Cell Cycle, Mitotic—MAD1L1—testicular cancer	1.3e-05	0.00574	CbGpPWpGaD
Paclitaxel—Decreased appetite—Doxorubicin—testicular cancer	1.29e-05	0.000131	CcSEcCtD
Paclitaxel—Gastrointestinal disorder—Doxorubicin—testicular cancer	1.28e-05	0.00013	CcSEcCtD
Paclitaxel—Fatigue—Doxorubicin—testicular cancer	1.28e-05	0.00013	CcSEcCtD
Paclitaxel—Urticaria—Epirubicin—testicular cancer	1.28e-05	0.00013	CcSEcCtD
Paclitaxel—Pain—Doxorubicin—testicular cancer	1.27e-05	0.000129	CcSEcCtD
Paclitaxel—Constipation—Doxorubicin—testicular cancer	1.27e-05	0.000129	CcSEcCtD
Paclitaxel—Abdominal pain—Epirubicin—testicular cancer	1.27e-05	0.000129	CcSEcCtD
Paclitaxel—Body temperature increased—Epirubicin—testicular cancer	1.27e-05	0.000129	CcSEcCtD
Paclitaxel—Hypersensitivity—Methotrexate—testicular cancer	1.26e-05	0.000128	CcSEcCtD
Paclitaxel—BCL2—Direct p53 effectors—MMP2—testicular cancer	1.25e-05	0.0055	CbGpPWpGaD
Paclitaxel—Asthenia—Methotrexate—testicular cancer	1.23e-05	0.000125	CcSEcCtD
Paclitaxel—Feeling abnormal—Doxorubicin—testicular cancer	1.22e-05	0.000124	CcSEcCtD
Paclitaxel—Gastrointestinal pain—Doxorubicin—testicular cancer	1.22e-05	0.000123	CcSEcCtD
Paclitaxel—Pruritus—Methotrexate—testicular cancer	1.21e-05	0.000123	CcSEcCtD
Paclitaxel—TUBB4B—Cell Cycle, Mitotic—MAD1L1—testicular cancer	1.19e-05	0.00525	CbGpPWpGaD
Paclitaxel—Hypersensitivity—Epirubicin—testicular cancer	1.18e-05	0.00012	CcSEcCtD
Paclitaxel—Urticaria—Doxorubicin—testicular cancer	1.18e-05	0.00012	CcSEcCtD
Paclitaxel—Abdominal pain—Doxorubicin—testicular cancer	1.17e-05	0.000119	CcSEcCtD
Paclitaxel—Body temperature increased—Doxorubicin—testicular cancer	1.17e-05	0.000119	CcSEcCtD
Paclitaxel—Diarrhoea—Methotrexate—testicular cancer	1.17e-05	0.000119	CcSEcCtD
Paclitaxel—TUBB4A—Cell Cycle—MAD1L1—testicular cancer	1.17e-05	0.00514	CbGpPWpGaD
Paclitaxel—Asthenia—Epirubicin—testicular cancer	1.15e-05	0.000117	CcSEcCtD
Paclitaxel—Pruritus—Epirubicin—testicular cancer	1.14e-05	0.000115	CcSEcCtD
Paclitaxel—Dizziness—Methotrexate—testicular cancer	1.13e-05	0.000115	CcSEcCtD
Paclitaxel—BCL2—Innate Immune System—BCL10—testicular cancer	1.1e-05	0.00485	CbGpPWpGaD
Paclitaxel—Diarrhoea—Epirubicin—testicular cancer	1.1e-05	0.000112	CcSEcCtD
Paclitaxel—TUBB—Cell Cycle, Mitotic—H2AFZ—testicular cancer	1.1e-05	0.00483	CbGpPWpGaD
Paclitaxel—Hypersensitivity—Doxorubicin—testicular cancer	1.09e-05	0.000111	CcSEcCtD
Paclitaxel—Vomiting—Methotrexate—testicular cancer	1.09e-05	0.000111	CcSEcCtD
Paclitaxel—Rash—Methotrexate—testicular cancer	1.08e-05	0.00011	CcSEcCtD
Paclitaxel—Dermatitis—Methotrexate—testicular cancer	1.08e-05	0.00011	CcSEcCtD
Paclitaxel—Headache—Methotrexate—testicular cancer	1.08e-05	0.000109	CcSEcCtD
Paclitaxel—Asthenia—Doxorubicin—testicular cancer	1.07e-05	0.000108	CcSEcCtD
Paclitaxel—TUBB4B—Cell Cycle—MAD1L1—testicular cancer	1.07e-05	0.0047	CbGpPWpGaD
Paclitaxel—Dizziness—Epirubicin—testicular cancer	1.06e-05	0.000108	CcSEcCtD
Paclitaxel—Pruritus—Doxorubicin—testicular cancer	1.05e-05	0.000107	CcSEcCtD
Paclitaxel—CYP3A5—Biological oxidations—HPGDS—testicular cancer	1.03e-05	0.00453	CbGpPWpGaD
Paclitaxel—Vomiting—Epirubicin—testicular cancer	1.02e-05	0.000104	CcSEcCtD
Paclitaxel—Nausea—Methotrexate—testicular cancer	1.02e-05	0.000103	CcSEcCtD
Paclitaxel—Diarrhoea—Doxorubicin—testicular cancer	1.02e-05	0.000103	CcSEcCtD
Paclitaxel—Rash—Epirubicin—testicular cancer	1.01e-05	0.000103	CcSEcCtD
Paclitaxel—Dermatitis—Epirubicin—testicular cancer	1.01e-05	0.000103	CcSEcCtD
Paclitaxel—Headache—Epirubicin—testicular cancer	1.01e-05	0.000102	CcSEcCtD
Paclitaxel—Dizziness—Doxorubicin—testicular cancer	9.83e-06	9.97e-05	CcSEcCtD
Paclitaxel—TUBB—Cell Cycle—H2AFZ—testicular cancer	9.8e-06	0.00432	CbGpPWpGaD
Paclitaxel—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	9.72e-06	0.00429	CbGpPWpGaD
Paclitaxel—Nausea—Epirubicin—testicular cancer	9.54e-06	9.68e-05	CcSEcCtD
Paclitaxel—Vomiting—Doxorubicin—testicular cancer	9.45e-06	9.59e-05	CcSEcCtD
Paclitaxel—Rash—Doxorubicin—testicular cancer	9.37e-06	9.51e-05	CcSEcCtD
Paclitaxel—Dermatitis—Doxorubicin—testicular cancer	9.36e-06	9.5e-05	CcSEcCtD
Paclitaxel—Headache—Doxorubicin—testicular cancer	9.31e-06	9.45e-05	CcSEcCtD
Paclitaxel—TUBB4A—Cell Cycle, Mitotic—H2AFZ—testicular cancer	9.09e-06	0.004	CbGpPWpGaD
Paclitaxel—CYP2C8—Biological oxidations—HPGDS—testicular cancer	8.91e-06	0.00393	CbGpPWpGaD
Paclitaxel—SLCO1B3—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	8.86e-06	0.00391	CbGpPWpGaD
Paclitaxel—Nausea—Doxorubicin—testicular cancer	8.83e-06	8.96e-05	CcSEcCtD
Paclitaxel—ABCB11—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	8.34e-06	0.00368	CbGpPWpGaD
Paclitaxel—TUBB4B—Cell Cycle, Mitotic—H2AFZ—testicular cancer	8.31e-06	0.00366	CbGpPWpGaD
Paclitaxel—TUBB4A—Cell Cycle—H2AFZ—testicular cancer	8.12e-06	0.00358	CbGpPWpGaD
Paclitaxel—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	7.81e-06	0.00344	CbGpPWpGaD
Paclitaxel—TUBB4B—Cell Cycle—H2AFZ—testicular cancer	7.43e-06	0.00328	CbGpPWpGaD
Paclitaxel—CYP2C9—Biological oxidations—HPGDS—testicular cancer	7.25e-06	0.0032	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	7.14e-06	0.00315	CbGpPWpGaD
Paclitaxel—NR1I2—Gene Expression—H2AFZ—testicular cancer	6.65e-06	0.00293	CbGpPWpGaD
Paclitaxel—BCL2—Innate Immune System—KITLG—testicular cancer	6.64e-06	0.00293	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—BCL10—testicular cancer	6.41e-06	0.00283	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.29e-06	0.00277	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.27e-06	0.00276	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.06e-06	0.00267	CbGpPWpGaD
Paclitaxel—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	5.19e-06	0.00229	CbGpPWpGaD
Paclitaxel—BCL2—Innate Immune System—FGFR3—testicular cancer	4.94e-06	0.00218	CbGpPWpGaD
Paclitaxel—CYP3A4—Biological oxidations—HPGDS—testicular cancer	4.78e-06	0.00211	CbGpPWpGaD
Paclitaxel—TUBB2B—Metabolism of proteins—MMP2—testicular cancer	4.59e-06	0.00202	CbGpPWpGaD
Paclitaxel—TUBB6—Metabolism of proteins—MMP2—testicular cancer	4.59e-06	0.00202	CbGpPWpGaD
Paclitaxel—BCL2—Innate Immune System—KIT—testicular cancer	4.53e-06	0.002	CbGpPWpGaD
Paclitaxel—TUBB3—Metabolism of proteins—MMP2—testicular cancer	4.43e-06	0.00195	CbGpPWpGaD
Paclitaxel—TUBB2A—Metabolism of proteins—MMP2—testicular cancer	4.29e-06	0.00189	CbGpPWpGaD
Paclitaxel—TUBB1—Metabolism of proteins—MMP2—testicular cancer	4.2e-06	0.00185	CbGpPWpGaD
Paclitaxel—SLCO1B3—Metabolism—HPGDS—testicular cancer	3.95e-06	0.00174	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—KITLG—testicular cancer	3.87e-06	0.0017	CbGpPWpGaD
Paclitaxel—TUBB4A—Metabolism of proteins—MMP2—testicular cancer	3.77e-06	0.00166	CbGpPWpGaD
Paclitaxel—ABCB11—Metabolism—HPGDS—testicular cancer	3.71e-06	0.00164	CbGpPWpGaD
Paclitaxel—TUBB4B—Metabolism of proteins—MMP2—testicular cancer	3.45e-06	0.00152	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.42e-06	0.00151	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—FGFR3—testicular cancer	2.87e-06	0.00127	CbGpPWpGaD
Paclitaxel—SLCO1B3—Metabolism—STK11—testicular cancer	2.87e-06	0.00126	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—HPGDS—testicular cancer	2.8e-06	0.00124	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—HPGDS—testicular cancer	2.79e-06	0.00123	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.78e-06	0.00123	CbGpPWpGaD
Paclitaxel—ABCB11—Metabolism—STK11—testicular cancer	2.7e-06	0.00119	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—HPGDS—testicular cancer	2.7e-06	0.00119	CbGpPWpGaD
Paclitaxel—BCL2—Immune System—KIT—testicular cancer	2.64e-06	0.00116	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—HPGDS—testicular cancer	2.46e-06	0.00108	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—H2AFZ—testicular cancer	2.43e-06	0.00107	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—HPGDS—testicular cancer	2.43e-06	0.00107	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—KITLG—testicular cancer	2.24e-06	0.000987	CbGpPWpGaD
Paclitaxel—CYP19A1—Metabolism—STK11—testicular cancer	2.04e-06	0.000898	CbGpPWpGaD
Paclitaxel—ABCC1—Metabolism—STK11—testicular cancer	2.03e-06	0.000894	CbGpPWpGaD
Paclitaxel—CYP1B1—Metabolism—STK11—testicular cancer	1.96e-06	0.000864	CbGpPWpGaD
Paclitaxel—ABCG2—Metabolism—STK11—testicular cancer	1.78e-06	0.000786	CbGpPWpGaD
Paclitaxel—CYP3A7—Metabolism—STK11—testicular cancer	1.77e-06	0.000779	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—HPGDS—testicular cancer	1.76e-06	0.000775	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—FGFR3—testicular cancer	1.66e-06	0.000734	CbGpPWpGaD
Paclitaxel—ABCC1—Disease—KIT—testicular cancer	1.53e-06	0.000674	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—HPGDS—testicular cancer	1.52e-06	0.000672	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—HPGDS—testicular cancer	1.33e-06	0.000585	CbGpPWpGaD
Paclitaxel—CYP3A5—Metabolism—STK11—testicular cancer	1.28e-06	0.000563	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—HPGDS—testicular cancer	1.24e-06	0.000547	CbGpPWpGaD
Paclitaxel—CYP2C8—Metabolism—STK11—testicular cancer	1.11e-06	0.000488	CbGpPWpGaD
Paclitaxel—ABCB1—Metabolism—STK11—testicular cancer	9.65e-07	0.000425	CbGpPWpGaD
Paclitaxel—CYP2C9—Metabolism—STK11—testicular cancer	9.01e-07	0.000397	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—HPGDS—testicular cancer	8.18e-07	0.00036	CbGpPWpGaD
Paclitaxel—CYP3A4—Metabolism—STK11—testicular cancer	5.94e-07	0.000262	CbGpPWpGaD
